Immune-targeted treatment plus chemotherapy for acute leukemia of unknown origin
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of targeted immune therapy and chemotherapy for a rare type of acute leukemia. The goal is to see if this approach can help people whose leukemia does not fit into the usual categories, potentially improving their chances of remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 14 years old.
- You have a type of acute leukemia that doctors have not been able to clearly classify (often called 'ambiguous lineage').
- You are generally able to do daily activities (not bedridden) — this is measured by an ECOG score of 0, 1, or 2.
- Your liver, kidneys, and heart are working well enough (based on blood tests and an echocardiogram).
- You agree to sign an informed consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Hear when a new Adult ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.